KR950700414A - 사람 인터루킨-4에 대한 사람화 모노클로날 항체의 클로닝 및 발현(Cloning and expression of humanized monoclonal antibodies against human interleukin-4) - Google Patents

사람 인터루킨-4에 대한 사람화 모노클로날 항체의 클로닝 및 발현(Cloning and expression of humanized monoclonal antibodies against human interleukin-4)

Info

Publication number
KR950700414A
KR950700414A KR1019940702925A KR19940702925A KR950700414A KR 950700414 A KR950700414 A KR 950700414A KR 1019940702925 A KR1019940702925 A KR 1019940702925A KR 19940702925 A KR19940702925 A KR 19940702925A KR 950700414 A KR950700414 A KR 950700414A
Authority
KR
South Korea
Prior art keywords
human interleukin
pct
monoclonal antibodies
cloning
expression
Prior art date
Application number
KR1019940702925A
Other languages
English (en)
Other versions
KR0158240B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR950700414A publication Critical patent/KR950700414A/ko
Application granted granted Critical
Publication of KR0158240B1 publication Critical patent/KR0158240B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1019940702925A 1992-02-19 1993-02-18 사람 인터루킨-4에 대한 사람화 모노클로날 항체의 클로닝 및 발현 KR0158240B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84165992A 1992-02-19 1992-02-19
US7/841,659 1992-02-19
PCT/US1993/001301 WO1993017106A1 (en) 1992-02-19 1993-02-18 Cloning and expression of humanized monoclonal antibodies against human interleukin-4

Publications (2)

Publication Number Publication Date
KR950700414A true KR950700414A (ko) 1995-01-16
KR0158240B1 KR0158240B1 (ko) 1998-11-16

Family

ID=25285411

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702925A KR0158240B1 (ko) 1992-02-19 1993-02-18 사람 인터루킨-4에 대한 사람화 모노클로날 항체의 클로닝 및 발현

Country Status (18)

Country Link
US (2) US5863537A (ko)
EP (1) EP0627002B1 (ko)
JP (1) JPH07502901A (ko)
KR (1) KR0158240B1 (ko)
CN (1) CN1076966A (ko)
AT (1) ATE171472T1 (ko)
AU (1) AU684041B2 (ko)
CA (1) CA2130436C (ko)
DE (1) DE69321218T2 (ko)
DK (1) DK0627002T3 (ko)
ES (1) ES2121078T3 (ko)
HK (1) HK1008831A1 (ko)
IL (1) IL104782A0 (ko)
MX (1) MX9300913A (ko)
NZ (1) NZ249677A (ko)
SG (1) SG52215A1 (ko)
WO (1) WO1993017106A1 (ko)
ZA (1) ZA931148B (ko)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502901A (ja) * 1992-02-19 1995-03-30 シェリング・コーポレーション ヒトインターロイキン−４に対するヒト化モノクローナル抗体のクローニング及び発現
EP0604693A1 (en) * 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en) * 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
BR9407575A (pt) * 1993-09-07 1996-07-16 Smithkline Beecham Corp Recombinaçao il4 de anticorpos uteis no tratamento de desordens do il4
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
IL140701A0 (en) 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using antibodies to aminophospholipids
EP1173790A2 (en) * 1999-03-01 2002-01-23 Boston Innovative Optics, Inc. System and method for increasing the depth of focus of the human eye
EP2292665B1 (en) 2000-05-26 2015-07-08 Immunex Corporation Use of interleukin-4 antibodies and compositions thereof
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
DK1537146T3 (da) 2002-07-15 2011-04-04 Univ Texas Antistoffer, der binder til anioniske phospholipider og aminophospholipider, og deres anvendelse til behandling af virusinfektioner
AU2003287622A1 (en) * 2002-11-06 2004-06-03 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
JP4741242B2 (ja) 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
EP2192172B1 (en) 2003-02-03 2014-12-03 iBio, Inc. System for expression of genes in plants
WO2004089988A2 (en) * 2003-04-03 2004-10-21 Protein Design Labs, Inc Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
ES2427641T3 (es) 2003-05-22 2013-10-31 Ibio, Inc. Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana
US7628810B2 (en) * 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
US20050046794A1 (en) * 2003-06-17 2005-03-03 Silvestrini Thomas A. Method and apparatus for aligning a mask with the visual axis of an eye
ES2532609T3 (es) * 2004-02-20 2015-03-30 Ibio, Inc. Sistemas y métodos para expresión clonales en plantas
ES2376556T3 (es) * 2004-03-24 2012-03-14 Abbott Biotherapeutics Corp. Utilización de la anticuerpos anti-alfa5beta1 para inhibir la proliferación de las células cancerosas.
AR050044A1 (es) 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
US7976577B2 (en) * 2005-04-14 2011-07-12 Acufocus, Inc. Corneal optic formed of degradation resistant polymer
CA2616859C (en) * 2005-08-03 2015-04-14 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
WO2007085815A2 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
CA2642056A1 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Hpv antigens, vaccine compositions, and related methods
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
EP1984405A4 (en) * 2006-02-13 2010-06-30 Fraunhofer Usa Inc INFLUENZA ANTIGENS, VACCINE COMPOSITIONS AND ASSOCIATED METHODS
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
ES2666650T3 (es) 2006-12-29 2018-05-07 OstéoQC Inc. Métodos para alterar el crecimiento óseo mediante la administración de antagonista o agonista de sost o wise
BRPI0810865A2 (pt) * 2007-04-28 2017-05-09 Fraunhofer Usa Inc antígenos de tripanossoma, composições vacinais, e métodos relacionados
CA2692933C (en) * 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
EP2193148A2 (en) * 2007-07-27 2010-06-09 Facet Biotech Corporation Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
EP2427479B1 (en) 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
ES2970433T3 (es) * 2009-08-13 2024-05-28 Acufocus Inc Método de fabricación de implantes intraoculares con máscara y lentes
CA2776144C (en) 2009-09-29 2020-10-27 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
USD656526S1 (en) 2009-11-10 2012-03-27 Acufocus, Inc. Ocular mask
US9057728B2 (en) 2011-07-12 2015-06-16 Epitomics, Inc. FACS-based method for obtaining an antibody sequence
US9545303B2 (en) 2011-12-02 2017-01-17 Acufocus, Inc. Ocular mask having selective spectral transmission
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
EP2920148B1 (en) 2012-11-16 2019-06-12 The Regents of the University of California Pictet-spengler ligation for protein chemical modification
US9204962B2 (en) 2013-03-13 2015-12-08 Acufocus, Inc. In situ adjustable optical mask
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
CN103421747B (zh) * 2013-09-09 2015-01-07 扬州大学 分泌牛il-4单克隆抗体的杂交瘤细胞株、其单克隆抗体及其应用
WO2015050663A1 (en) 2013-10-01 2015-04-09 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of bim
JP6745218B2 (ja) 2013-11-27 2020-08-26 レッドウッド バイオサイエンス， インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
US10124070B2 (en) 2014-06-06 2018-11-13 Redwood Bioscience, Inc. Anti-HER2 antibody-maytansine conjugates and methods of use thereof
WO2016014148A1 (en) 2014-07-23 2016-01-28 Mayo Foundation For Medical Education And Research Targeting dna-pkcs and b7-h1 to treat cancer
WO2016065329A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
US9982057B2 (en) 2014-11-17 2018-05-29 Pelican Therapeutics, Inc. Human TNFRSF25 antibody
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
US20190209697A1 (en) 2015-11-05 2019-07-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
CA3026652A1 (en) 2016-06-09 2017-12-14 Pelican Therapeutics, Inc. Anti-tnfrsf25 antibodies
US10240581B2 (en) 2017-02-08 2019-03-26 General Electric Company System and method for controlling pitch angle of a wind turbine rotor blade
CN110540590B (zh) * 2018-05-29 2023-08-18 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制物的开发和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
IL89489A0 (en) * 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9105292D0 (en) * 1991-03-13 1991-04-24 Sandoz Ltd Improvements in or relating to organic compounds
JPH07502901A (ja) * 1992-02-19 1995-03-30 シェリング・コーポレーション ヒトインターロイキン−４に対するヒト化モノクローナル抗体のクローニング及び発現

Also Published As

Publication number Publication date
WO1993017106A1 (en) 1993-09-02
US5863537A (en) 1999-01-26
IL104782A0 (en) 1993-06-10
US5770403A (en) 1998-06-23
JPH07502901A (ja) 1995-03-30
AU3666293A (en) 1993-09-13
EP0627002B1 (en) 1998-09-23
DE69321218D1 (de) 1998-10-29
HK1008831A1 (en) 1999-05-21
NZ249677A (en) 1996-08-27
ZA931148B (en) 1993-08-18
MX9300913A (es) 1994-08-31
AU684041B2 (en) 1997-12-04
SG52215A1 (en) 1998-09-28
ES2121078T3 (es) 1998-11-16
EP0627002A1 (en) 1994-12-07
KR0158240B1 (ko) 1998-11-16
CN1076966A (zh) 1993-10-06
ATE171472T1 (de) 1998-10-15
DE69321218T2 (de) 1999-02-18
DK0627002T3 (da) 1999-06-14
CA2130436A1 (en) 1993-09-02
CA2130436C (en) 2001-04-10

Similar Documents

Publication Publication Date Title
KR950700414A (ko) 사람 인터루킨-4에 대한 사람화 모노클로날 항체의 클로닝 및 발현(Cloning and expression of humanized monoclonal antibodies against human interleukin-4)
MY108526A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
DK0812333T3 (da) Bispecifikt antistof, som er effektivt til behandling af B-cellelymfom og cellelinie
FI960567A (fi) Monoklonaalinen vasta-aine, joka indusoi apoptoosin
ATE283926T1 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
ATE175241T1 (de) Antikörper gegen alpha v beta 3 integrin
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
DE69229278D1 (de) Humanisierter b-b10, ein anti-il-2-rezeptor-antikörper
FI944509A (fi) Interferonireseptorin vastaisia monoklonaalisia vasta-aineita, joilla on neutralisoivaa aktiivisuutta tyypin I interferonia vastaan
ES2121358T3 (es) Anticuerpos monoclonales humanizados contra interleuquina-4 humana.
FR2664702B1 (fr) Procede de reduction d'interferences dans un dosage par fluorescence.
NO964015L (no) Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
DK0725837T3 (da) Adeno-associeret virus - dettes diagnostiske anvendelse ved tidlig abort
DE69334036D1 (de) Hybridom und humanisierter monoklonaler anti-kc-4-antikörper, dafür kodierende dnas und rnas, kit und diagnostische verfahren
HUP9903273A3 (en) Anti-human mp52 monoclonal antibody
FI956041A (fi) Kompositiot ja diagnostiset menetelmät, joissa käytetään monoklonaalisia vasta-aineita CD44V6 vastaan

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee